SAB Biotherapeutics SABS
NASDAQ SABS
$2.98 -0.08 (-2.61%)
At close: Oct 2, 2026 · 4:00 PM EDT

SAB Biotherapeutics (SABS) Price to Earnings (2025)

Updated

SAB Biotherapeutics' Price to Earnings came in at 5.44 for Q4 2025, up 375.9% from the prior quarter.

Analysis

SAB Biotherapeutics (SABS) Price to Earnings (2025) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,076.25 Bn 1,044.84 Bn 19.71 Bn
2 Johnson & Johnson 617.18 Bn 535.70 Bn 17.26 Bn
3 AbbVie 464.58 Bn 437.73 Bn 12.70 Bn
4 Merck 356.04 Bn 310.47 Bn 12.21 Bn
5 Novartis Ag 269.07 Bn 224.94 Bn 11.24 Bn
6 Astrazeneca 243.21 Bn 216.77 Bn 12.86 Bn
7 Amgen 217.88 Bn 173.28 Bn 7.24 Bn
8 Gilead Sciences 179.62 Bn 153.74 Bn 6.22 Bn
9 Pfizer 158.45 Bn 105.40 Bn 10.94 Bn
10 SAB Biotherapeutics 248.81 Mn 248.81 Mn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2025 5.44
Sep 30, 2025 1.14
API Access

SAB Biotherapeutics Price to Earnings API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=price-to-earnings&ticker=SABS&period=max&api_key=YOUR_API_KEY